We further demonstrated robust and significant attenuation of tumor growth by a BTZ/navitoclax/carboplatin combination regimen in Onc-p53 H1975, but not WT p53 H460, xenografts (Fig. 5D and E), consistent with our hypothesis that PI/BH3 mimetic–based therapy is specifically active in NSCLC tumors bearing Onc-p53. This evidence concerns the gene TP53 and neoplasm.